Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III trial of ChAdOx1 SARS-CoV-2 Vaccine for COVID-2019-infections

Next Previous
Trial Profile

Phase II/III trial of ChAdOx1 SARS-CoV-2 Vaccine for COVID-2019-infections

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 1222 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 02 Oct 2020 According to an AstraZeneca media release, the recommendations of an independent committee have been supported by the international regulators, who have deemed that this trial is safe to resume.
  • 02 Oct 2020 Status changed from suspended to recruiting, according to an AstraZeneca media release.
  • 12 Sep 2020 According to an AstraZeneca media release, the Company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top